{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:17:42Z","timestamp":1791656262995,"version":"4.3.4"},"reference-count":33,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Methadone is an analgesic drug used for pain treatment and heroin substitution. Recently, methadone has been proposed to be useful also for cancer therapy, including glioblastoma multiforme (GBM), the most severe form of brain cancer, because experiments on cultured glioma cells treated with doxorubicin showed promising results. Doxorubicin, however, is not used first-line in GBM therapy. Therefore, we analyzed the cytotoxic effect of methadone alone and in combination with temozolomide, a DNA-alkylating drug that is first-line used in GBM treatment, utilizing GBM-derived cell lines and a human fibroblast cell line. We show that methadone is cytotoxic on its own, inducing apoptosis and necrosis, which was observed at a concentration above 20 \u00b5g\/mL. Methadone was similar toxic in isogenic MGMT expressing and non-expressing cells, and in LN229 glioblastoma and VH10T human fibroblasts. The apoptosis-inducing activity of methadone is not bound on the opioid receptor (OR), since naloxone, a competitive inhibitor of OR, did not attenuate methadone-induced apoptosis\/necrosis. Administrating methadone and temozolomide together, temozolomide had no impact on methadone-induced apoptosis (which occurred 3 days after treatment), while temozolomide-induced apoptosis (which occurred 5 days after treatment) was unaffected at low (non-toxic) methadone concentration (5 \u00b5g\/mL), and at high (toxic) methadone concentration (20 \u00b5g\/mL) the cytotoxic effects of methadone and temozolomide were additive. Methadone is not genotoxic, as revealed by comet and \u03b3H2AX assay, and did not ameliorate the genotoxic effect of temozolomide. Further, methadone did not induce cellular senescence and had no effect on temozolomide-induced senescence. Although methadone was toxic on senescent cells, it cannot be considered a senolytic drug since cytotoxicity was not specific for senescent cells. Finally, we show that methadone had no impact on the MGMT promoter methylation. Overall, the data show that methadone on glioblastoma cells in vitro is cytotoxic and induces apoptosis\/necrosis at doses that are above the level that can be achieved in vivo. It is not genotoxic, and does not ameliorate the cell killing or the senescence-inducing effect of temozolomide (no synergistic effect), indicating it has no impact on temozolomide-induced signaling pathways. The data do not support the notion that concomitant methadone treatment supports temozolomide-based chemotherapy.<\/jats:p>","DOI":"10.3390\/ijms21197006","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T09:28:08Z","timestamp":1600853288000},"page":"7006","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-0809","authenticated-orcid":false,"given":"Bernd","family":"Kaina","sequence":"first","affiliation":[{"name":"Institute of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Beltzig","sequence":"additional","affiliation":[{"name":"Institute of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piee-Staffa","sequence":"additional","affiliation":[{"name":"Institute of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1213-3527","authenticated-orcid":false,"given":"Bodo","family":"Haas","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.hoc.2012.04.006","article-title":"Glioblastoma multiforme: Overview of current treatment and future perspectives","volume":"26","author":"Anton","year":"2012","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1158\/0008-5472.CAN-08-1227","article-title":"Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance","volume":"68","author":"Friesen","year":"2008","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.4161\/cc.28493","article-title":"Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma","volume":"13","author":"Friesen","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.21873\/anticanres.11438","article-title":"Safety and Tolerance of d,l-Methadone in Combination with Chemotherapy in Patients with Glioma","volume":"37","author":"Onken","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.dnarep.2007.03.008","article-title":"MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents","volume":"6","author":"Kaina","year":"2007","journal-title":"DNA Repair"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Knizhnik, A.V., Roos, W.P., Nikolova, T., Quiros, S., Tomaszowski, K.H., Christmann, M., and Kaina, B. (2013). Survival and death strategies in glioma cells: Autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055665"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair (Amst.)"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kaina, B. (2019). Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030069"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","article-title":"Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-kappaB","volume":"79","author":"Aasland","year":"2019","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.onc.1207080","article-title":"Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas\/CD95\/Apo-1","volume":"23","author":"Roos","year":"2004","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/ncb2344","article-title":"More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance","volume":"13","author":"Lukas","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/toxsci\/kfu066","article-title":"The gammaH2AX assay for genotoxic and nongenotoxic agents: Comparison of H2AX phosphorylation with cell death response","volume":"140","author":"Nikolova","year":"2014","journal-title":"Toxicol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2017.10.001","article-title":"Epigenetic regulation of DNA repair genes and implications for tumor therapy","volume":"780","author":"Christmann","year":"2019","journal-title":"Mutat. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/ijc.25229","article-title":"MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: A comparative study on astrocytoma and glioblastoma","volume":"127","author":"Christmann","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.18632\/oncotarget.952","article-title":"Cell death sensitization of leukemia cells by opioid receptor activation","volume":"4","author":"Friesen","year":"2013","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/vms3.266","article-title":"Methadone does not potentiate the effect of doxorubicin in canine tumour cell lines","volume":"6","author":"Cueni","year":"2020","journal-title":"Vet. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2005.03583.x","article-title":"MGMT and p53 status predict temozolomide sensitivity in human malignant glioma cells","volume":"96","author":"Hermisson","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/1541-7786.MCR-18-1306","article-title":"The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death","volume":"17","author":"He","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"He, Y., and Kaina, B. (2019). Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071562"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.1987.47","article-title":"Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain","volume":"41","author":"Inturrisi","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"CNS18","DOI":"10.2217\/cns-2018-0006","article-title":"Efficacy of d,l-methadone in the treatment of glioblastoma in vitro","volume":"7","author":"Brawanski","year":"2018","journal-title":"CNS Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-019-03816-3","article-title":"d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro","volume":"83","author":"Oppermann","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.onc.1209785","article-title":"Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine","volume":"26","author":"Roos","year":"2007","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s002800050842","article-title":"Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration","volume":"42","author":"Marzolini","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","article-title":"The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation","volume":"15","author":"Portnow","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1212\/01.WNL.0000127617.89363.84","article-title":"One week on\/one week off: A novel active regimen of temozolomide for recurrent glioblastoma","volume":"62","author":"Wick","year":"2004","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11910-012-0262-y","article-title":"Temozolomide dosing regimens for glioma patients","volume":"12","author":"Strik","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/exd.13543","article-title":"Methadone-Not a magic bullet in melanoma therapy","volume":"27","author":"Mangana","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13148-016-0204-7","article-title":"MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response","volume":"8","author":"Switzeny","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mrgentox.2017.07.004","article-title":"Genotoxicity testing: Comparison of the gammaH2AX focus assay with the alkaline and neutral comet assays","volume":"822","author":"Nikolova","year":"2017","journal-title":"Mutat. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7006\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:12:52Z","timestamp":1760177572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197006"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197006","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]}}}